Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : Alcon eye-care unit to enter Swiss index after spin off

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/05/2019 | 12:14pm EDT
FILE PHOTO: Swiss drugmaker Novartis' logo is seen in Stein

ZURICH (Reuters) - Alcon, the eye care business being spun-off by Novartis, will be included in the Swiss Market Index of Switzerland's 20 largest listed companies, market operator SIX said on Tuesday.

Information about any other changes to SMI and Switzerland's other indexes will be released later, the bourse said.

Novartis last year announced the spin off of Alcon to the Basel drugmaker's shareholders in the first half of this year.

Bank Vontobel analysts have said Alcon could be worth between $15 billion and $23 billion, adding its ongoing recovery would influence the final price.

(Reporting by John Revill; Editing by Edmund Blair)

Stocks mentioned in the article
ChangeLast1st jan.
NOVARTIS 0.08% 86.4 Delayed Quote.16.20%
SMI -0.16% 10032.49 Delayed Quote.18.84%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVARTIS
07:58aNOVARTIS : announces that Jakavi® (ruxolitinib) meets primary endpoint in Phase ..
PU
07:52aINCYTE : Says Phase 3 REACH2 Trial Meets Endpoint
DJ
06:17aFactbox - How are businesses preparing for a 'no-deal Brexit'?
RE
10/15NOVARTIS : Sandoz and Pear Therapeutics announce Pear will solely commercialize ..
AQ
10/14EUROPE : European stocks hit pause as trade doubts linger
RE
10/11NOVARTIS : data show Cosentyx treatment results in rapid and sustained resolutio..
AQ
10/10NOVARTIS : data show Cosentyx® treatment results in rapid and sustained resoluti..
PU
10/09NOVARTIS : real-world evidence confirms high efficacy, long-term response and fa..
AQ
10/09NOVARTIS : STEP Program now accepting submissions for proposals that address unm..
AQ
10/09NOVARTIS : real-world evidence confirms high efficacy, long-term response and fa..
PU
More news
Financials (USD)
Sales 2019 46 913 M
EBIT 2019 13 832 M
Net income 2019 9 642 M
Debt 2019 17 425 M
Yield 2019 3,42%
P/E ratio 2019 18,2x
P/E ratio 2020 19,8x
EV / Sales2019 4,59x
EV / Sales2020 4,28x
Capitalization 198 B
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 94,18  $
Last Close Price 86,43  $
Spread / Highest target 24,3%
Spread / Average Target 8,96%
Spread / Lowest Target -6,87%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS16.20%198 243
JOHNSON & JOHNSON1.29%350 587
ROCHE HOLDING AG19.25%248 542
MERCK AND COMPANY11.29%217 734
PFIZER-16.38%201 883
AMGEN5.13%122 735